Geode Capital Management
EFTR

Geode Capital Management’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Geode Capital Management’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,583
Closed -$7.42K – 4666
2024
Q2 		$7.42K Buy
25,583
+2,974
+13% +$7.06K ﹤0.01% 4557
2024
Q1 		$325K Buy
22,609
+6,290
+39% +$75.3K ﹤0.01% 3771
2023
Q4 		$191K Buy
16,319
+5,769
+55% +$77.3K ﹤0.01% 3959
2023
Q3 		$158K Buy
10,550
+6,351
+151% +$110K ﹤0.01% 4073
2023
Q2 		$87.2K Hold
4,199
– – ﹤0.01% 4378
2023
Q1 		$37.8K Sell
4,199
-55
-1% -$667 ﹤0.01% 4581
2022
Q4 		$45K Hold
4,254
– – ﹤0.01% 4624
2022
Q3 		$60K Hold
4,254
– – ﹤0.01% 4726
2022
Q2 		$151K Hold
4,254
– – ﹤0.01% 4414
2022
Q1 		$426K Buy
4,254
+422
+11% +$56.1K ﹤0.01% 4019
2021
Q4 		$793K Buy
3,832
+2,872
+299% +$667K ﹤0.01% 3821
2021
Q3 		$337K Buy
+960
New +$310K ﹤0.01% 4211

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management's EFTR Position: Q3 2024 in Review

Geode Capital Management sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 25,583 shares — an estimated $7.42K sold.

Geode Capital Management first reported a position in EFTR in Q3 2021 and held it in 12 quarters. The position peaked at $793K in Q4 2021. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

  • Geode Capital Management reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Geode Capital Management sold 25,583 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $7.42K.
  • Geode Capital Management first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
  • Geode Capital Management's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $793K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Geode Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.